REDWOOD CITY, Calif.
Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that medical device executive Jiayu Chen, Ph.D., has been named Vice President of Engineering and Advanced Technologies, effective immediately. Dr. Chen reports directly to President and CEO Christopher M. Owens.
Dr. Chen has more than 20 years of experience in the medical device industry with a particular emphasis on product development from concept to commercialization, IP development and ultrasound technology evaluation. Most recently, from 2013 to the present, Dr. Chen was a Chief Engineer at GE Ultrasound, a division of GE Healthcare. In that role he provided technical leadership and guidance on innovation and product strategies for research and development and clinical programs.
Prior to that, Dr. Chen spent 10 years (2003-2013) as Vice President of Engineering at Sunnyvale, CA-based U-Systems Inc, a manufacturer of ultrasound products for breast cancer applications that was purchased by GE Healthcare in November 2012. Dr. Chen built and managed a highly-talented engineering team and structured the company’s intellectual properties, among other duties.
Dr. Chen and his team at U-Systems Inc. delivered the first Premarket Approval (PMA) by the FDA of an automated breast ultrasound system.
“Jiayu’s proven track record of innovation along with his strategic vision will add significant expertise to our current and future technology platforms,” Owens said. “As we continue to thoughtfully scale the organization, his depth of knowledge in ultrasound technology, leadership and drive for collaboration will support new engineering development and clinical solutions, enhancing our product offerings, while creating a foundation of excellence. We look forward to working with Jiayu and his contribution to the continued success of the organization.”
Dr. Chen has a Masters of Science degree in mechanical engineering from Tsinghua University in China and a doctorate in electrical engineering from Pennsylvania State University.
About Sonata System
The Sonata™ System, the next generation of Gynesonics’ technology platform (the previous generation referred to as VizAblate), uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. The Sonata™ System, including the SMART Targeting Guide, enables the operator to target fibroids and optimize ablations within them. Sonata™ System’s design provides a straightforward, transcervical access for a uterus preserving, incision-free fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. In October 2014, Gynesonics announced FDA approval of the SONATA IDE pivotal trial for their latest generation Sonata™ System.
About Gynesonics
Gynesonics is a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Gynesonics has developed the Sonata™ System for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The Sonata™ System is CE Marked and approved for sale in the European Union. Sonata™ System is not available for sale in the United States. Gynesonics is a privately held company with headquarters in Redwood City, CA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160505005210/en/
CONTACT
Gynesonics
Chris Owens, +1 650-216-3860
President and CEO
www.gynesonics.com
